Elismetrep for migraine disorders

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 12 Jun 2026: Trial registered, NCT07645924
  2. 1 Jul 2026: Trial started, NCT07645924

The trials

NCT07645924: A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

State
Under way
Phase
Phase 3
People
1,800 planned
Started
1 Jul 2026
Primary completion
Feb 2027
Arms
Elismetrep 10 mg, Elismetrep 20 mg
Results
None posted
  1. 12 Jun 2026: Trial registered
  2. 1 Jul 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.